Effect of ketoconazole on the pharmacokinetics of oral bosutinib in healthy subjects

Journal of Clinical Pharmacology

Volumn 51, Issue 12, 2011, Pages 1721-1727

  Abbas, Richat ^a   Hug, Bruce A ^a   Leister, Cathie ^a   Burns, Jaime ^a   Sonnichsen, Daryl ^a  

^a PFIZER INC   (United States)

Author keywords

Bosutinib; CYP3A4 protein; drug interaction; human; ketoconazole; pharmacokinetics

Indexed keywords

BOSUTINIB; KETOCONAZOLE;

ADJUVANT THERAPY; ADULT; ARTICLE; CROSSOVER PROCEDURE; DIZZINESS; DRUG CLEARANCE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; EVENING DOSAGE; EXCORIATION; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; INCIDENCE; MALE; MONOTHERAPY; MORNING DOSAGE; NAUSEA; OPEN STUDY; POLLAKURIA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ADULT; ANILINE COMPOUNDS; ANTIFUNGAL AGENTS; AREA UNDER CURVE; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; HUMANS; KETOCONAZOLE; MALE; MIDDLE AGED; NITRILES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; QUINOLINES; YOUNG ADULT;

EID: 82955187886     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010387427     Document Type: Article

References (17)

1. Frame MC. Src in cancer: deregulation and consequences for cell behaviour. Biochim Biophys Acta. 2002 ; 1602: 114-130 (Pubitemid 34521791)
2. Avizienyte E, Frame MC. Src and FAK signalling controls adhesion fate and the epithelial-to-mesenchymal transition. Current Opin Cell Biol. 2005 ; 17: 542-547 (Pubitemid 41267169)
3. Windham TC, Parikh NU, Siwak DR, et al. Src activation regulates anoikis in human colon tumor cell lines. Oncogene. 2002 ; 21: 7797-7807 (Pubitemid 35398837)
4. Fizazi K. The role of Src in prostate cancer. Ann Oncol. 2007 ; 18: 1765-1773 (Pubitemid 350119560)
5. Homsi J, Cubitt C, Daud A. The Src signaling pathway: a potential target in melanoma and other malignancies. Expert Opin Ther Targets. 2007 ; 11: 91-100 (Pubitemid 46099755)
6. Pendergast AM. The Abl family kinases: mechanisms of regulation and signaling. Adv Cancer Res. 2002 ; 85: 51-100
7. Hantschel O, Superti-Furga G. Regulation of the c-Abl and Bcr-Abl tyrosine kinases. Nat Rev Mol Cell Biol. 2004 ; 5: 33-44 (Pubitemid 38089839)
8. Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet. 2000 ; 38: 41-57 (Pubitemid 30055093)
9. von Moltke LL, Greenblatt DJ, Schmider J, et al. Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. J Clin Pharmacol. 1996 ; 36: 783-791 (Pubitemid 26329500)
10. United States Food and Drug Administration (FDA). Drug Interaction Studies-Study Design, Data Analysis, and Implications for Dosing and Labeling. Rockville, MD: FDA Center for Drug Evaluation and Research; 2006. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm072101.pdf. October 10, 2010.
11. Bjornsson TD, Callaghan JT, Einolf HJ, et al. The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. J Clin Pharmacol. 2003 ; 43: 443-469 (Pubitemid 36506147)
12. Chien JY, Lucksiri A, Ernest CS, Gorski JC, Wrighton SA, Hall SD. Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole. Drug Metab Dispos. 2006 ; 34: 1208-1219 (Pubitemid 43922328)
13. Oo C, Chen Y-C. The need for multiple doses of 400 mg ketoconazole as a precipitant inhibitor of a CYP3A substrate in an in vivo drug-drug interaction study. J Clin Pharmacol. 2009 ; 49: 368-369
14. Evans WE, Schentag JJ, Jusko WJ Principles of Therapeutic Drug Monitoring. 3 rd ed.Vancouver, WA: Applied Therapeutics, Inc; 1992. Vancouver, WA: Applied Therapeutics, Inc ; 1992 :
15. Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D. Ascending single-dose study of safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy subjects. Poster presented at: 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference ; Boston, MA ;..
16. Daneshmend TK, Warnock DW, Turner A, Roberts CJ. Pharmacokinetics of ketoconazole in normal subjects. J Antimicrob Chemother. 1981 ; 8: 299-304 (Pubitemid 12201573)
17. Nizoral 200 mg tablet [package insert]. Taro Pharmaceuticals, USA; 2008. http://www.drugs.com/pro/ketoconazole-tablets.html. Accessed August 4, 2010.